January 28, 2021 BetterLife Engages Eurofins Discovery for its Next Generation Psychedelics 2-bromo-LSD FDA IND-enabling Pharmacology Studies
January 26, 2021 BetterLife Demonstrates 6 months Refrigerated Stability of its Proprietary Interferon Formulation to be Developed to Treat Early Stage Covid-19 Cases
January 21, 2021 BetterLife Selects CRO to Conduct Clinical Trials for AP-003 in COVID-19 Cases in Indonesia
January 7, 2021 BetterLife Announces Formation of Next Generation Psychedelic Research Advisory Board
January 4, 2021 BetterLife Files Patent for the Treatment of MDD Utilizing its Second-Generation Psychedelic Derivative for 2-Bromo-LSD
December 21, 2020 BetterLife Closes Acquisition of Second Generation Psychedelic Assets of Transcend Biodynamics LLC
November 10, 2020 Pre-IND Discussion with U.S. FDA Helps BetterLife Set Up AP-003 Clinical Trials in Australia
